1.350USD-4.93%Mkt Cap: 144.61M $P/E: —1d ago
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrume…
Industry Peers
Medical DevicesIndicators:|
Key Statistics
Company
Market Cap144.61M $
Enterprise Value55.25M $
Revenue (TTM)32.29M $
Gross Profit26.80M $
Net Income (TTM)-44.63M $
Revenue/Share0.3030 USD
Last Price1.350 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees91
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.73
PEG—
EV/EBITDA-1.62
EV/Revenue1.71
P/S4.48
P/B0.86
EPS (TTM)-0.36
EPS (Forward)-0.24
52W Range
0.643041% of range2.370
52W High2.370 USD
52W Low0.6430 USD
Profitability
Gross Margin81.16%
Oper. Margin-64.09%
EBITDA Margin-105.80%
Profit Margin-135.14%
ROE-26.02%
ROA-22.04%
Growth
Revenue Growth-7.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-34.41M $
CapEx (TTM)1.77M $
FCF Margin-43.76%
FCF Yield-9.77%
Net Debt-89.37M $
Net Debt/EBITDA2.62
Balance Sheet
Debt/Equity0.10
Current Ratio12.04
Quick Ratio10.88
Book Value/Sh1.567 USD
Cash/Share0.9980 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.107 USD
Upside (mean)+204.3%
Target Range2.430 USD – 5.000 USD
$2.430+204.3% to mean$5.000
# Analysts4
Ownership
Shares Out.107.12M
Float97.63M
Insiders1.59%
Institutions68.16%
Short Interest
Short Ratio1.0d
Short % Float1.43%
Short % Out.1.41%
Shares Short1.52M
Short (prev mo.)4.47M
Technical
SMA 501.136 (+18.9%)
SMA 2001.193 (+13.1%)
Beta1.66
S&P 52W Chg20.25%
Avg Vol (30d)1.33M
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)62.6
MACD0.0703
MACD Signal0.0611
MACD Hist.+0.0092
BB Upper1.429 USD
BB Middle1.260 USD
BB Lower1.090 USD
BB Width26.97%
ATR (14)0.0861 USD
Vol Ratio (20d)0.64x